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Abstract
Background: Blood for transfusion is a frequently used clinical intervention, and is also a costly and limited
resource with risks. Many transfusions are given to stable and non-bleeding patients despite no clear evidence of
benefit from clinical studies. Audit and feedback (A&F) is widely used to improve the quality of healthcare,
including appropriate use of blood. However, its effects are often inconsistent, indicating the need for coordinated
research including more head-to-head trials comparing different ways of delivering feedback. A programmatic
series of research projects, termed the ‘Audit and Feedback INterventions to Increase evidence-based Transfusion
practIcE’ (AFFINITIE) programme, aims to test different ways of developing and delivering feedback within an
existing national audit structure.
Methods: The evaluation will comprise two linked 2×2 factorial, cross-sectional cluster-randomised controlled trials.
Each trial will estimate the effects of two feedback interventions, ‘enhanced content’ and ‘enhanced follow-on
support’, designed in earlier stages of the AFFINITIE programme, compared to current practice. The interventions
will be embedded within two rounds of the UK National Comparative Audit of Blood Transfusion (NCABT) focusing
on patient blood management in surgery and use of blood transfusions in patients with haematological malignancies.
The unit of randomisation will be National Health Service (NHS) trust or health board. Clusters providing care relevant
to the audit topics will be randomised following each baseline audit (separately for each trial), with stratification for size
(volume of blood transfusions) and region (Regional Transfusion Committee). The primary outcome for each topic will
be the proportion of patients receiving a transfusion coded as unnecessary. For each audit topic a linked,
mixed-method fidelity assessment and cost-effectiveness analysis will be conducted in parallel to the trial.
Discussion: AFFINITIE involves a series of studies to explore how A&F may be refined to change practice including
two cluster randomised trials linked to national audits of transfusion practice. The methodology represents a step-wise
increment in study design to more fully evaluate the effects of two enhanced feedback interventions on patient- and
trust-level clinical, cost, safety and process outcomes.
Trial registration: http://www.isrctn.com/ISRCTN15490813
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Background
Blood transfusion is a common intervention in clinical
practice, but transfusions are also a costly and limited
resource. The most frequently transfused blood compo-
nent is red cells, but audits of practice continue to docu-
ment administration of red cells to groups of stable and
non-bleeding patients despite the lack of clear evidence
of benefit from clinical trials [1, 2]. Unnecessary transfu-
sion exposes patients to risk, well described by haemovi-
gilance systems such as Serious Hazards of Transfusion
(SHOT) in UK, with impacts on mortality and morbid-
ity, through errors in administration and processing,
transfusion transmitted infections, acute lung injury and
circulatory overload [3, 4].
Active strategies are usually needed to close the gap
between recommended and actual clinical practice [5].
Audit and feedback (A&F) is one such widely used ap-
proach, defined as a summary of the clinical performance
of healthcare providers over a specified period of time
[6]. In England, the National Health Service Blood and
Transplant (NHSBT) National Comparative Audit (NCA)
programme has supported a series of national audits
designed to assess whether blood components are used
appropriately and safely across clinical specialties [7].
Although participation is voluntary, there are high
levels of participation in NCABT audits. Two or three
times a year an audit-writing group is assembled, usu-
ally comprising an audit lead (typically a consultant
haematologist with an interest in transfusion), statisti-
cian and clinical staff representatives from the clinical
specialty being audited (e.g. orthopaedics). This group
agrees upon audit standards against which clinical prac-
tice will be compared, the data to be collected and the
findings and recommendations to be included in feed-
back reports. Resulting feedback reports are subse-
quently made available to the hospital transfusion team
(i.e. transfusion practitioner, consultant haematologist,
transfusion laboratory manager) via a hospital-specific
NCABT audit webpage. Each team is subsequently re-
sponsible for disseminating reports within its hospital
and, where feedback indicates discrepancies between
current practice and audit standards, leading action to
improve practice [8].
Despite this rolling programme of national audits,
around 20% of transfusions continue to fall outside recom-
mended practice [9, 10], consistent with other international
experience [1]. Amongst several possibilities, one likely key
explanation for this lack of progress is the variable effect-
iveness of A&F as an intervention. A Cochrane review of
140 randomised trials found that A&F had modest effects
on patient processes of care, leading to a median of 4.3%
absolute improvement in compliance with recommended
practice (interquartile range 0.5 to 16%). One quarter of
A&F interventions had a relatively large, positive effect on
quality of care, while another quarter had a negative or null
effect. The reasons behind this variation are only partially
understood, and further research is needed to improve the
consistency and magnitude of the effects of A&F. Further-
more, the relative paucity of head-to-head comparisons of
different methods of providing feedback makes it difficult
to recommend the use of one feedback strategy over an-
other on empirical grounds [6, 11].
The AFFINITIE programme, ‘Audit and Feedback INter-
ventions to Increase evidence-based Transfusion practice,’
aims to develop and evaluate different ways of delivering
feedback embedded in the existing series of audits con-
ducted by the NCABT. The overarching goal is to pro-
mote the uptake of evidence-based transfusion guidance
and to reduce the unnecessary use of blood components.
The AFFINITIE programme follows the UK Medical
Research Council (MRC) Framework for the design and
evaluation of complex interventions [12] and comprises
four work streams with the following objectives:
1. To develop, pilot and refine two feedback interventions,
referred to as ‘enhanced content’ and ‘enhanced
follow-on support’ [13];
2. To evaluate effectiveness and cost-effectiveness of
the two enhanced feedback interventions compared
with current standard feedback practice;
3. To investigate the intervention fidelity, including
mechanisms of change, for the evaluated
interventions [8];
4. To develop general implementation recommendations
and tools for relevant A&F programmes in the
wider NHS.
This paper describes the second of these work streams,
evaluating the effectiveness and cost-effectiveness of en-
hanced feedback interventions.
Methods/design
Study design and setting
The evaluation comprises two linked, 2×2 factorial, cross-
sectional, cluster-randomised controlled trials (cRCTs)
embedded within the NHS NCABT. The two transfusion
topics, transfusions in surgical and haematological pa-
tients, respectively, were identified and planned by the
usual processes conducted by the NCABT. Alongside each
audit, we will evaluate two multi-component feedback in-
terventions (enhanced content or enhanced follow-on
support) which may be applied singly or in combination;
these will be compared with standard feedback, where
neither intervention is delivered. Enhanced interven-
tions were developed and piloted in Work Stream 1 of
the AFFINITIE Programme based on relevant theory
and evidence related to A&F [13]. All feedback,
whether enhanced or standard, is directed at clinical
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teams within hospital trusts and health boards across
the UK. The effects of feedback will be assessed using a
range of clinical, cost, safety and process end-points.
Figure 1 shows the trial CONSORT diagram whilst the
full trial protocol is available as Additional file 1.
NHS Trusts and Health Boards can consist of more
than one hospital which is covered by a single Hospital
Transfusion Team. In addition, several NHS Trusts may
share the same Hospital Transfusion Team. Therefore,
the unit of randomisation (i.e. cluster) is NHS trust or
health board, or group of NHS trusts, to minimise the
contamination risk resulting from feedback being di-
rected at a Hospital Transfusion Team that may work
across hospitals or NHS Trusts. We adopted, by neces-
sity, a cross-sectional design in which different patients
(i.e. cases) are audited at baseline and follow-up (given
that it is unlikely that the same patients will receive
transfusions during both periods). While there may be
some overlap in clinical staff involved in transfusing pa-
tients within a cluster over time, a cross-sectional design
is assumed here too. Eligible clusters may take part in
one or both transfusion audits and associated trials.
Trial participants
Inclusion criteria are: (i) provision of an NHS service
relevant to an audit topic and (ii) acceptance of the in-
vitation by the NCA to participate in the audit. Inde-
pendent hospitals are not eligible for participation in
AFFINITIE, as clinicians involved in transfusion decisions
at the NHS trusts and health boards are also likely to
practice at independent hospitals, potentially leading to
contamination. We will also exclude four NHS trusts
that participated in earlier intervention development work.
They will still be invited to take part in the national audits
and will receive both enhanced feedback interventions.
Recruitment
Clusters
The NCABT will invite NHS trusts and health boards to
participate in the audit. The AFFINITIE team will subse-
quently contact the appropriate transfusion or haematol-
ogy clinical lead at all sites participating in the audit.
This letter will explain that the AFFINITIE program is
conducting research to enhance existing quality im-
provement methods and that involves randomising sites
to different types of feedback from the NCABT. We will
further explain that the research team will contact the
relevant research and development department to seek
necessary permissions and that the clinical lead need
take no further action. Sites declining participation in
the randomised evaluation will be excluded but continue
to participate in the NCABT. If the clinical lead has not
declined participation within 2 weeks, we will assume
that they wish to be included in the study. The
AFFINITIE team will seek to obtain permission from the
sites that have expressed an interest, or have not de-
clined to participate in the research.
We will document and report reasons for non-
participation. Where at least one hospital site within a
trust or health board is eligible, the trust or health board
will be regarded as eligible. Where multiple hospital sites
are eligible within a trust or health board, or where
multiple hospitals are known to share a Transfusion
Team, the NCABT may treat them as separate but we
will regard them as a single cluster for the purposes of
randomisation and analysis.
Randomisation
As part of the 2×2 design, participating trusts and health
boards will be randomised to one of four arms: (i)
‘standard content’ and ‘standard follow-on support’; (ii)
‘standard content’ and ‘enhanced follow-on support’; (iii)
‘enhanced content’ and ‘standard follow-on support’; and
(iv) ‘enhanced content’ and ‘enhanced follow-on support’.
The randomisations will follow baseline data collection in
the two audits. The Clinical Trials Research Unit (CTRU)
will use an automated system to randomise eligible,
consenting trusts and health boards on a 1:1:1:1 basis.
A computer-generated minimisation programme, incorp-
orating a random element, will be used to ensure inter-
vention arms are balanced for the following cluster-level
characteristics:
 Trust or health board size based on number of audit
cases. For each audit, we will review the number of
cases submitted to baseline audit per cluster, break
these down into thirds (large, medium and small)
and later report the final cut-off points used.
 Regional Transfusion Committee (RTC). These
cover geographical regions and undertake activities
to promote good transfusion practice and to oversee
local Hospital Transfusion Committees.
The second transfusion topic (haematology patients)
will be used to guide whether the results from the first
audit (surgical patients) evaluation can be generalised.
We will randomise the four trial arms to clusters separ-
ately for each transfusion audit topic, using a “split-block”
design [14], rather than keep the allocations the same
across topics within trusts/health boards. This design sep-
arates the effects of the feedback interventions from time
and topic to produce unbiased estimates of effects across
trials, increasing the robustness of conclusions drawn
from the second trial. The randomised allocation to the
first trial will be an additional stratification factor in the
randomisation to the second trial. If trusts or health
boards merge following randomisation in each trial, they
will continue to be regarded as separate and distinct
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Fig. 1 AFFINITIE—CONSORT flow diagram
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clusters for the intervention, data collection and analysis
of that trial. Clusters that merge between trials will be
reviewed and a decision made on whether to continue to
regard them as distinct clusters in the second trial.
Changes will be accounted for in a sensitivity analysis.
Following each randomisation, the CTRU will inform
the NCABT, the Chief Investigators and the intervention
delivery team of allocations so that appropriate arrange-
ments can be made for intervention delivery as soon as
feasible. Other personnel involved in the trial will only
be informed of the trial allocation if this is required to
undertake their role. We will maintain a log of who is
unblinded at specific points in the research process.
Feedback interventions
Standard feedback
Current practice is defined as the standard feedback
content and follow-on support delivered by the NCABT
following completion of an audit, targeting clinical teams
within organisations. Feedback is typically in the form of
a written clinical audit report made available via a
hospital-specific NCABT audit webpage, a regional
PowerPoint presentation and (sometimes) action plan
templates. The content of the written report varies, de-
pending on the audit (and will be described in detail).
How these clinical teams and organisations respond fol-
lowing receipt of the feedback is regarded as a conse-
quence of the trial interventions—but is presently
considered to be variable. We expect them to respond in
the context of their clinical governance arrangements.
Standard follow-on support involves dealing with data
queries from hospitals and is provided by the NCABT
Programme Manager. No restrictions will be imposed on
current practice or on trusts or health boards undertaking
additional development or training in the provision of
feedback, with the exception that we will request that the
staff who receive the feedback do not share it with col-
leagues external to their own trust or health board. We
will assess and describe the detail of standard feedback
content and follow-on within each trial as part of the
process evaluation [8].
Enhanced content
The enhanced content intervention for each trial has
been developed using the current evidence base for A&F
[6] and behaviour change theory [15, 16].
The enhanced content concerns the content and format
of feedback reports delivered to hospitals and consists of
two components. Firstly, the NCABT audit-writing group
will receive an enhancement guidance manual, which in-
cludes guidance on how to apply proposed enhancements
for writing feedback reports with evidence- and theory-
based content. Secondly, is the resulting feedback report,
which is uploaded to each hospital’s individual NCABT
webpage, where target intervention recipients (i.e. hospital
transfusion team) can access and download their feedback
reports [8, 13].
The proposed enhancements were identified following
a content analysis of previous NCA feedback reports.
This examined whether effective components of A&F,
identified in the Cochrane Review, and behaviour change
techniques (BCTs), consistent with control theory [15]
(e.g. goal-setting, feedback, action planning) featured in
existing reports [13]. It is intended that the audit-writing
group will apply the enhancement guidance manual to
produce a template feedback report with enhanced
content, which will subsequently be populated with
hospital-specific audited data in the feedback report.
Where it is possible we will minimise bias by restrict-
ing knowledge of intervention allocation to those who
need to know in order to implement the trial.
During intervention development, the members of the
enhanced and standard feedback writing groups will be
aware which intervention they are developing, however,
they will not know which ‘clusters’ are going to receive
their intervention until it has been delivered.
Following release of feedback, there is a risk of con-
tamination (e.g. from communication between members
of the enhanced and standard feedback report writing
groups). However, we will discourage communication
pertaining to feedback content between the two writing
groups and remind all participants of equipoise (i.e. it is
not known whether one feedback method is superior).
Enhanced follow-on support
The enhanced follow-on support intervention for each
trial concerns the actions taken in hospitals in response
to feedback reports. It aims to support relevant hospital
transfusion staff response to feedback. It comprises a
web-based toolkit for use by the hospital transfusion
team. The toolkit aims to facilitate three behaviours in
response to feedback: dissemination of findings to all
relevant clinical staff involved in transfusion decision-
making; goal-setting, problem solving and action plan-
ning to facilitate practice changes in response to feed-
back; and continued monitoring of the clinical practices
that were audited. The toolkit will be accessible to hos-
pital staff via a web-link uploaded to each hospital’s indi-
vidual NCABT webpage. As a co-intervention to prompt
engagement with the toolkit, hospital transfusion teams
will receive an initial telephone support call from an
intervention facilitator, offering support and advice on
how to use the toolkit. A telephone line will subse-
quently be available for hospitals to contact intervention
facilitators for further support as needed.
Both types of enhanced feedback can be provided in-
dependently as well as in combination, as part of the
2×2 trial design.
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Endpoints
The primary outcome for each audit topic is whether a
transfusion is categorised as necessary or not (binary
measure) and will be measured at the patient level based
on the NCABT follow-up audit.
A clinical algorithm for determining if a transfusion is
necessary or not will be agreed upon by an independent
panel of two clinicians and a statistician, based on clin-
ical relevance and adherence to recommended practice
in the baseline audit. The panel will be presented with a
description of candidate endpoints, instructed to discuss
their clinical relevance and merits, and suggest candidate
endpoints to consider further. For these endpoints, we
will present the panel with summary information on
baseline achievement of the endpoint and the sample
size of the final candidate endpoints to ensure that the
selected endpoint does not unacceptably reduce the
sample size or power below levels allowed for in sample
size calculation. The panel members will vote for their
preferred outcomes after reviewing the final candidate
endpoints. The outcomes with majority support will be
selected and documented as the trial primary endpoints,
thereby minimising the risk of detection bias.
For the surgical audit, transfusion may occur pre-
operatively, intra-operatively or post-operatively. There
may also be multiple transfusion episodes after surgery
but prior to discharge. As all patients will have had one
or more transfusions over the entire operative period
(14 days prior to surgery to 7 days following surgery),
the primary outcome is whether any of the pre-operative
and post-operative transfusions were unnecessary versus
all pre-operative and post-operative transfusions being
necessary (binary).
For the haematology audit, patients experiencing mul-
tiple transfusions of a similar type within the audit
period will be audited once only for one of those events.
Patient transfused with both red cells and platelets in
the audit period will be audited for both. The primary
outcome is whether any of these transfusions were un-
necessary versus all transfusions being necessary (binary).
For both trials, the Statistical Analysis Plan will specify
the statistical programming needed to derive the primary
outcome from the patient-level NCABT audit. No clinical
judgement will be required at a patient-level to categorise
transfusions as necessary or not.
Table 1 outlines the secondary, supportive, intermedi-
ate and process level outcomes.
Data collection
Audit data
Data collected for the NCABT will contribute towards
the baseline and follow-up trial data. Existing NCABT
procedures for developing a topic-specific audit tool
for data collection will be followed. These include
convening an Audit Writing Group supported by the
NCABT Programme Manager to develop evidence-
based audit criteria, ensuring the objectivity of data
items collected to minimise observation bias, and in-
corporating appropriate logic and use of compulsory
fields into the online audit tool to maximise the return
of complete datasets. The data items collected will de-
pend on the standardised decision algorithm developed
for each topic and will include basic patient demo-
graphic variables. In line with standard practice, case
identification and data collection will be piloted and
refined as necessary. Best practice NCABT guidance
will be given to trusts and health boards on case identifi-
cation and data collection, with training recommended
and available via the NCABT website. Data collectors will
complete the audit tools for all retrievable cases identified
by the NCABT.
For each topic, there will be a baseline audit and a
follow-up audit approximately 12 months following ran-
domisation. The follow-up audit will include the subset
of the items included in the baseline audit required to
calculate trial outcomes.
The NCABT will provide the CTRU with four fully
anonymised patient-level datasets, covering the baseline
and follow-up audits for each of the two transfusion
topics. Data will be provided in electronic format via a
secure file transfer system. The CTRU will run the end-
point algorithms.
Blood Stock Management Scheme (BSMS) collects
data in relation to blood stock and wastage management
from hospitals in England. The CTRU will request
hospital-level datasets which will cover the period
12 months before and 12 months after the feedback is
made available to NHS trusts and health boards. The
data will be provided in electronic format, via a secure
file transfer system, and will include the following variables:
month; laboratory; hospital; trust or health board; hospital
profile (including electronic/manual cross-matching, cross-
match reservation period, cell salvage availability, RTC);
blood group; gross issue, net issue, wastage and transfused
data for red cells, platelets and adult fresh frozen plasma
(FFP).
Serious Hazards of Transfusion (SHOT) is a UK-wide
haemovigilance scheme, which collects anonymised data
on adverse events and reactions associated with the
transfusion of blood and blood components. The CTRU
will request fully anonymised patient-level datasets
which will cover the period 12 months prior to and
12 months after feedback is made available. The data
will again be provided in electronic format, via a secure
file transfer system. It will include: incident identifier;
patient identifier; speciality; cluster identifier; date of
transfusion; blood components transfused and/or impli-
cated component(s); source of component (blood service
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donor, autologous, directed donation); primary diagnosis
for the component transfusion event (adverse event,
pathological reaction, transfusion transmitted infection,
pulmonary complication of transfusion); type of incident
(event, near miss, right blood right patient); date of inci-
dent; status (pathological reaction which may not be
preventable; probably or possibly preventable by im-
proved practice and monitoring; or adverse event caused
by error). For each incident type, data will be collected
on investigations, treatments, support and outcomes to
facilitate estimates of the costs and health outcomes of
transfusion related adverse events for use as inputs into
the health economic modelling. We will request this in-
cident data, already stripped of trust and health board
identifiers.
The CTRU will use BSMS and SHOT data to derive
baseline and outcome variables of interest for the tri-
als (Table 1). Once trust-level datasets have been
linked, and prior to performing or reporting any ana-
lyses, all identifiers will be removed and trusts and
health boards will only be identified by unique con-
secutive identifiers.
Contamination events
There is a potential for contamination of interventions,
i.e. site staff receiving standard feedback being exposed
to enhanced feedback. Contamination between interven-
tion and control arms may occur at up to six levels:
 Hospital Transfusion Team (e.g. Transfusion
Practitioners) communicate with colleagues in other
NHS trusts and health boards as part of their role;
 NHS BT Patient Blood Management Practitioners
communicate with colleagues in other NHS trusts
and health boards;
 Clinical Audit Leads;
 NCABT writing group;
 Clinical staff—junior medical staff training and on
rotation between different units and senior medical
staff working across different sites;
Table 1 Secondary, supportive and intermediate outcomes
Surgical audit
Secondary outcomes • Total volume of allogeneic red cells transfused (units at trust-level; units at patient-level);
• Total number of incidents reported to SHOT (count at trust-level);
• Number of definitely, probably or possibly preventable incidents reported to SHOT within
clinical specialties targeted by the audit (count at trust-level)
Supportive outcomes • Pre-operative transfusion (unnecessary/necessary)
• Post-operative transfusion (unnecessary/necessary)
• Individual NCA audit standard met
• Total volume of red cells issued (units at trust-level)
• Total volume of red cells wasted (units at trust-level)
Intermediate outcomes (mediators) Include:
• Whether the planned surgery date equals the actual surgery date
• Volume of post-operative cell salvage transfused
• Hb level
• Length of post-operative hospital stay
Trust process level data • Intervention fidelity
• Organizational structures and resources
• Tier of data collectors
Haematology audit
Secondary outcomes • Total volume of allogeneic red cells transfused (units at trust-level; units at patient-level);
• Total volume of platelets transfused (units at patient-level);
• Total number of incidents reported to SHOT (count at trust-level);
• Number of definitely, probably or possibly preventable incidents reported to SHOT within
clinical specialties targeted by the audit (count at trust-level)
Supportive outcomes • Red cell transfusion alone (unnecessary/necessary)
• Platelet transfusion alone (unnecessary/necessary)
• Individual NCA audit standard met
• Total volume of red cells issued (units at trust-level)
• Total volume of red cells wasted (units at trust-level)
• Total volume of platelets issued (units at trust-level)
• Total volume of platelets wasted (units at trust-level)
Intermediate outcomes (mediators) Include:
• Whether the Hb level was checked after each unit was transfused
• Whether the platelet count was measured after each unit was transfused
Trust process level data • Intervention fidelity
• Organizational structures and resources
• Tier of data collectors
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 NCABT Programme Manager and Statistician;
 The AFFINITIE trial team.
We will assess the respective risks and impacts of con-
tamination at each level. We will take several steps to
minimise such risk and we will check for, and monitor,
any interactions within the wider AFFINITIE team that
may also risk contamination. We will use a combination
of brief interviews, observations and diaries to gather
data suggesting contamination and to inform interpret-
ation of trial findings.
Organisational survey
The NCABT will collect data at timelines corresponding
to the baseline and follow-up on structural and resource
factors which may influence local adherence to recom-
mended practice (e.g. availability of cell salvage) and to
inform the health economic evaluations.
Data collectors
Data will be collected on the role of the data collector
and will be categorised as follows: tier 1 (Hospital Trans-
fusion Team or Committee); tier 2 (audit department, la-
boratory); tier 3 (senior clinicians): tier 4 (junior doctors);
and tier 5 (nursing staff ).
Data on intervention delivery
These are described in the process evaluation protocol [8].
Resource use and costs
We will collect resource use data to undertake the health
economic analyses (Table 2).
Sample size
For each topic, there are two principal comparisons of
interest (enhanced content vs. standard content; and en-
hanced follow-on support vs. standard follow-on support)
relating to the two main effects of the 2×2 factorial design.
Assuming 20% unnecessary transfusions at follow-up for
each topic [3, 4], an intra-cluster correlation (ICC) of 0.05
and cluster sizes varying from 17 to 68 with a mean of 45,
we need 152 clusters to detect a minimally important
reduction of 6% (i.e. to 14% unnecessary transfusions)
in the presence of, at most, a small antagonistic statistical
interaction [17] (i.e. 10% or fewer unnecessary transfusions
in the enhanced content and follow-on support) with 80%
power using logistic regression models, a random-intercept
for cluster, and a 2-sided 2.5% significance level for each
comparison within each model. This requires us to recruit
from England, Wales, Scotland and Northern Ireland and
allows 12/171 (7%) clusters to be ineligible and 95% of
those eligible to consent and be randomised. If these as-
sumptions do not all hold, the full trial protocol illustrates
the impact on the minimally important clinical difference
the trial would be powered to detect (Additional file 1).
Statistical analysis
General considerations
Before any formal analysis, a detailed Statistical Analysis
Plan (SAP) will be agreed by the statisticians, the Chief
Investigator, other appropriate members of the research
team and the Trial Steering Committee.
We expect the proportion of missing data to be non-
trivial, making the handling of missing data an important
analytical issue. As a sizeable proportion of patients are
expected to be missing and the missing data predictable
by known variables, we will use multiple imputation under
a missing at random (MAR) assumption. Sensitivity ana-
lyses will be carried out as appropriate.
As the primary clinical effectiveness analysis for each
topic has a single primary outcome but two main treat-
ment effects, two-sided 2.5% significance levels will be
used for these contrasts. Where results are subsequently
combined when interpreting the treatment effect, we will
consider the family-wise error rate and adjustments will
be made for multiplicity.
Cluster randomisation imposes recruitment-related
clustering. As the impact of clustering is expected to be
Table 2 Resource use data to be collected on intervention delivery
Item Measures of resource use Additional notes
Audit data collection Time of hospital personnel (data collectors)
recorded for a sub-sample
Job title and the time taken to extract the audit data
from case notes or hospital information systems will
be collected on the audit data collection form
To minimise burden on sites, the time taken to enter
the data onto the NCA system will be estimated by
having NCA personnel enter data for a number of
‘mock’ audit cases
Development and delivery of
standard content feedback and
enhanced content feedback
Time of NCA personnel in designing and
populating documents with audit data,
including the NCA audit writing groups
and associated support
The NCA clinical audit leads and statistician team
will record the amount of time taken to perform
each of these activities.
Delivery of the enhanced follow-on
support
Time of personnel delivering and receiving
the enhanced follow-on support, including
the web-based toolkit plus telephone support
AFFINITIE team members delivering the enhanced
follow-on support will record the duration of telephone
support and the use of the online toolkit
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equal across arms, the principal method for handling
this will be to fit a multilevel model that constrains the
cluster- and patient-level variances to be equal across
arms, that is, a random-intercept model.
No interim analyses are planned. The two audit trans-
fusion topics will be regarded as two trials, but also with
a single final analysis when all follow-up data from both
topics has been databased, cleaned and locked.
Data distributions will be summarised, cluster and patient-
level CONSORT diagrams generated and characteristics
of clusters and individuals at baseline and follow-up
summarised by arm and by intervention.
The primary analyses will be carried out on an intention-
to-treat basis, utilising all available follow-up data from all
patients and imputing unavailable follow-up data, compar-
ing allocated interventions. A complier average causal effect
(CACE) analysis, comparing treatments received, will be
considered if more than 10% of clusters do not implement
the intervention as intended.
Primary endpoint analysis
For each topic independently, the patient-level binary
primary outcome of unnecessary transfusions 12 months
following randomisation will be analysed using logistic
regression, with a random intercept for trust/health board,
adjusting for design factors (that is, trust size, regional
transfusion committee), and trust-level proportion of
unnecessary transfusions at baseline, with contrasts for:
(1) enhanced content vs. standard content; (2) enhanced
follow-on support vs. standard follow-on support; and the
interaction between (1) and (2), regardless of statistical
significance.
Secondary endpoint analyses
Patient-level secondary endpoints of volume transfused
(both red cells and platelets) will be analysed using a
Poisson random-intercept regression model, with the same
contrasts and covariates as in the primary endpoint ana-
lysis. Trust-level secondary endpoints (volume transfused,
number of SHOT-reportable incidents and number of def-
initely, probably or possibly preventable incidents reported
to SHOT within clinical specialities targeted by the audit)
will be analysed using cluster-level analyses recognising the
outcomes are all counts.
Further secondary analyses
Exploratory analyses will be conducted investigating me-
diators (e.g. fidelity: delivery, receipt and enactment) and
moderators (e.g. trust size) of the main effects of the two
feedback interventions in the surgical and haematological
audits.
A number of exploratory sub-group analyses are planned,
which will be specified in detail in the SAP. These include
trust and health board and patient level factors such as
trust size, Transfusion Practitioner involvement, surgical
procedure and haematological diagnosis.
Sensitivity analysis will be undertaken to investigate how
contamination events, such as merging hospital trusts,
might affect the size and direction of primary outcome
measure.
Process evaluation
In the AFFINITIE programme, the process evaluation
will focus on the assessment of fidelity using the fidelity
framework proposed by the NIH Behaviour Change
Consortium (BCC) [18, 19] to investigate and report the
extent to which feedback interventions were designed,
trained, delivered, received and enacted as intended.
Two linked process evaluations will be conducted along-
side the two linked cluster randomised trials [8].
Economic evaluation
Design
Two cost-effectiveness analyses (one for each trial) will
be conducted using decision analytic modelling from the
perspective of the NHS. We will compare the costs and
effects of all four feedback options (standard content
feedback, enhanced content only, enhanced follow-on
support only and enhanced content and enhanced follow-
on support).
Methods
Trial-based economic evaluation is not feasible as no
unique set of patients is identified at the start of the trial
and followed until study completion. Modelling is there-
fore required to simulate costs and outcomes associated
with each option. The models will be developed follow-
ing a literature review of previously published models of
transfusion, and in accordance with good practice guide-
lines for decision modelling [20].
The models will combine decision tree and Markov
approaches and will simulate the main hypothesised
costs and effects. These include the costs associated with
each intervention, changes in unnecessary transfusions
and associated adverse events, plus changes in practice that
were introduced to facilitate the change in transfusions.
Resource use data will be collected as specified above.
The trials will provide data on the impact of the inter-
ventions on transfusions and transfusion-associated ad-
verse events. Data on the volumes of blood components
transfused to each audit case will be used to estimate
the mean number of product units per unnecessary
transfusion. Data from published studies, expert clinical
opinion, SHOT and the BSMS will be used to estimate
the probabilities, costs, utilities and survival of transfusion-
related adverse events. Unit costs will be taken from
published sources [21–24].
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Analysis
We will undertake cost-effectiveness and cost-utility ana-
lyses; the former based on primary and secondary out-
comes in the trials, the latter based on quality-adjusted life
years. A lifetime horizon will be used, with appropriate
discounting. We will undertake deterministic and prob-
abilistic sensitivity analysis, the latter assigning appropriate
distributions to uncertain model parameters [25].
Cost effectiveness acceptability curves will identify
the intervention most likely to be cost-effective for dif-
ferent values of willingness to pay for additional health
gain.
Trial status
The trials are currently in progress. No transfer of end-
point data or cleaning has yet occurred.
Discussion
The AFFINITIE trials illustrate how to advance scientific
knowledge on the effectiveness and cost-effectiveness of
A&F through a rigorous evaluation embedded within a
national implementation programme. A cumulative meta-
analysis of A&F trials indicated that effect sizes stabilised
over 10 years ago, suggesting a lack of cumulative learning
on how to improve effectiveness [26]. There is now an
empirically and theoretically informed research agenda for
interventions such as A&F and an acknowledged need to
move beyond “business as usual” [27]. This includes
undertaking head-to-head trials to compare different ap-
proaches to feedback content and delivery, as set out in
this protocol.
AFFINITIE is also an example of an ‘implementation la-
boratory’ that involves close collaboration between a health
system delivering an implementation strategy at scale and
a research team [11]. This approach offers several mutual
advantages. First, by merit of building upon an existing im-
plementation programme and harnessing data already be-
ing collected, AFFINITIE will make efficient use of
research funding. Second, this close partnership between
the NCABT and the research team throughout all stages of
the research process will enable knowledge transfer and
the subsequent uptake of evidence about implementation
into organisational policies and practice [28]. Third, the
wide coverage of and high levels of hospital participation
in the NCABT will underpin ‘real world’ generalisability.
Fourth, it will provide opportunities for parallel mixed-
method process evaluations to provide critical insights into
mechanisms of change which can inform further research
and practice [8].
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